- Conditions
- Cutaneous Sarcoidosis, Granuloma Annulare
- Interventions
- Tofacitinib 5 mg twice daily
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Granuloma Annulare
- Interventions
- AC-1101
- Drug
- Lead sponsor
- TWi Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Granuloma Annulare
- Interventions
- Not listed
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Keloid, Scleroderma, Localized, Acne Keloidalis, Scars, Granuloma Annulare
- Interventions
- UVB Irradiation
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 10 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
- Interventions
- Corticosteroid with lidocaine, Corticosteroid with normal saline
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Granuloma Annulare
- Interventions
- Abrocitinib 200 mg
- Drug
- Lead sponsor
- William Damsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Sarcoidosis, Granuloma Annulare
- Interventions
- Deucravacitinib
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Keloid, Scleroderma, Scars, Granuloma Annulare, Acne Keloidalis Nuchae
- Interventions
- German manufactured UVA1 emitting light system
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 10 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan